---
schema_version: "secwatch.filing_event.v1"
accession: "0000009326-25-000012"
form_type: "8-K"
ticker: "BCPC"
cik: "0000009326"
company_name: "BALCHEM CORP"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:41:37.527542+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat

## Summary
- Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.
- Record adjusted EBITDA $69.2M (+11.2%); adjusted EPS $1.27 vs $1.09.
- All three segments grew; record sales and earnings in Human Nutrition & Health and Specialty Products.
- Plans new $36M micro-encapsulation facility in Orange County, NY, pending county approval.
- EU imposes provisional anti-dumping duties of 95.4%-120.8% on Chinese choline chloride imports effective July 1, 2025.

## SEC filing metadata
- accession: 0000009326-25-000012
- form_type: 8-K
- ticker: BCPC
- cik: 0000009326
- company_name: BALCHEM CORP
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/9326/000000932625000012/0000009326-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/9326/000000932625000012/bcpc-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000009326-25-000012
- JSON: https://secwatch.observer/filing/0000009326-25-000012.json
- Plain text: https://secwatch.observer/filing/0000009326-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.